Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | GFER | P55789 | 3/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312971 | 0.87 | KDM4E (0.71) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL29466392 | 0.87 | KDM4E (0.71) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL25876071 | 0.86 | KDM4E (0.73) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL3663283 | 0.86 | CLK1 (0.66) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL25884758 | 0.83 | KDM4E (0.62) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL15101533 | 0.83 | SMN1; SMN2 (0.67) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL25311377 | 0.83 | KDM4E (0.62) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL25263897 | 0.83 | KDM4E (0.65) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL28933829 | 0.82 | ALDH1A1 (0.78) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL25878920 | 0.82 | KDM4E (0.67) | CLK1DYRK1AKDM4ERAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022057932-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-03-24 | — | — | WO | disclosed |
| WO-2022057928-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-03-24 | — | — | WO | disclosed |
| CN-114195780-A | Carbonyl heterocyclic compound and application thereof | 上海医药集团股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195806-A | Carbonyl heterocyclic compound and application thereof | 上海医药集团股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LANCL2, CBS, LCP2 | CLK1 1025/4885DYRK1A 4468/4885KDM4E 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.